Update on SARS-CoV-2 Vaccination for Kidney Transplant Recipients

  • 1 Victoria Hall, MBBS, is a Transplant Infectious Diseases Fellow with Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada. Deepali Kumar, MD, is Professor of Medicine and Infectious Diseases with Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
Restricted access

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has had a significant impact on transplantation, with mortality rates in transplant recipients ranging from 10% to 20% (1). Although some antiviral and anti-inflammatory therapies for COVID-19 have become available, they need to be given within a short time window during the course of illness to be effective (2, 3). Thus, the recent US Food and Drug Administration (FDA) Emergency Use Authorization of highly efficacious mRNA-based SARS-CoV-2 vaccines by Pfizer/BioNTech and Moderna provides hope for reducing infection rates (4).

Both

Save